Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,longTermDebt,accountsPayable,otherAssets,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,gmtOffSetMilliseconds,esgPopulated,tradeable,market,exchange,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,priceHint,marketState,exchangeDataDelayedBy,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,EQ,91880000.0,29040300,5880000,,-8991000,,-8991000,2815000,0,-8695000,-8695000,,-271000,,,,0,0,8695000,0,-296000,,-8991000,-8991000,172049000.0,14958000.0,91880000.0,106838000.0,2000.0,-79916000.0,35000.0,-255000.0,50861000.0,7417000.0,2500000.0,-255000.0,223000.0,106615000.0,53218000.0,7506000.0,2324000.0,,4860000.0,-489000.0,4860000.0,29964000.0,261000.0,29964000.0,26879000.0,-1000.0,-7944000.0,17000.0,1194000.0,,99198000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,1.3008118,6.1 - 6.285,6.15,6.18,6.31,8,8,finmb_575585027,NasdaqGM,"Equillium, Inc.",USD,137012,296166,-14400000,False,False,us_market,NGM,-1.358,-1.54,-1.32,-4.719697,3.164,5.7708335,0.45916653,0.07956676,6.4944925,-0.2644925,-0.040725663,180921072,-4.0454545,1.9690266,15,America/New_York,EDT,6.23,1630509750,0.07999992,6.13,6.285,6.1,19232,"Equillium, Inc.",2,REGULAR,0,2.76,0.79538906,3.47 - 11.33,-5.1,-0.4501324,3.47,11.33,1620921721,1636369140,1636718400,1.62,,,11.33,3.47,5.77,6.49,137.01k,296.17k,29.04M,,17.96M,52.99%,30.00%,1.14M,9.13,7.18%,3.91%,778.35k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-24.55%,-48.30%,,,,,-30.74M,-30.97M,-1.36,,104.08M,3.58,10.01M,10.89,14.37,3.16,-26.2M,-14.91M,Value,92037,Healthcare,31,"Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.",La Jolla,858 412 5302,CA,1609372800,United States,http://equilliumbio.com,86400,2223 Avenida De La Playa,Biotechnology,Suite 105
t-1,EQ,69854000.0,29040300,6567000,,-8918000,,-8918000,2403000,0,-8970000,-8970000,,-276000,,,,0,0,8970000,0,52000,,-8918000,-8918000,141074000.0,15574000.0,69854000.0,85428000.0,2000.0,-70925000.0,54000.0,-297000.0,23982000.0,7245000.0,1666000.0,-297000.0,239000.0,85174000.0,58181000.0,8275000.0,2766000.0,15000.0,-17006000.0,1123000.0,-17036000.0,11000.0,-1172000.0,11000.0,-25267000.0,11000.0,-8253000.0,17000.0,632000.0,-30000.0,77929000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,1.3008118,6.1 - 6.285,6.15,6.18,6.31,8,8,finmb_575585027,NasdaqGM,"Equillium, Inc.",USD,137012,296166,-14400000,False,False,us_market,NGM,-1.358,-1.54,-1.32,-4.719697,3.164,5.7708335,0.45916653,0.07956676,6.4944925,-0.2644925,-0.040725663,180921072,-4.0454545,1.9690266,15,America/New_York,EDT,6.23,1630509750,0.07999992,6.13,6.285,6.1,19232,"Equillium, Inc.",2,REGULAR,0,2.76,0.79538906,3.47 - 11.33,-5.1,-0.4501324,3.47,11.33,1620921721,1636369140,1636718400,1.62,,,11.33,3.47,5.77,6.49,137.01k,296.17k,29.04M,,17.96M,52.99%,30.00%,1.14M,9.13,7.18%,3.91%,778.35k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-24.55%,-48.30%,,,,,-30.74M,-30.97M,-1.36,,104.08M,3.58,10.01M,10.89,14.37,3.16,-26.2M,-14.91M,Value,92037,Healthcare,31,"Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.",La Jolla,858 412 5302,CA,1609372800,United States,http://equilliumbio.com,86400,2223 Avenida De La Playa,Biotechnology,Suite 105
t-2,EQ,78126000.0,29040300,4218000,,-6597000,,-6597000,2298000,0,-6516000,-6516000,,-276000,,,,0,0,6516000,0,-81000,,-6597000,-6597000,140161000.0,14259000.0,78126000.0,92385000.0,2000.0,-62007000.0,71000.0,-30000.0,49249000.0,5145000.0,833000.0,-30000.0,225000.0,92160000.0,41288000.0,9043000.0,1681000.0,,-22859000.0,-129000.0,-23016000.0,53063000.0,977000.0,53063000.0,25166000.0,40000.0,-4921000.0,13000.0,750000.0,-157000.0,87015000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,1.3008118,6.1 - 6.285,6.15,6.18,6.31,8,8,finmb_575585027,NasdaqGM,"Equillium, Inc.",USD,137012,296166,-14400000,False,False,us_market,NGM,-1.358,-1.54,-1.32,-4.719697,3.164,5.7708335,0.45916653,0.07956676,6.4944925,-0.2644925,-0.040725663,180921072,-4.0454545,1.9690266,15,America/New_York,EDT,6.23,1630509750,0.07999992,6.13,6.285,6.1,19232,"Equillium, Inc.",2,REGULAR,0,2.76,0.79538906,3.47 - 11.33,-5.1,-0.4501324,3.47,11.33,1620921721,1636369140,1636718400,1.62,,,11.33,3.47,5.77,6.49,137.01k,296.17k,29.04M,,17.96M,52.99%,30.00%,1.14M,9.13,7.18%,3.91%,778.35k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-24.55%,-48.30%,,,,,-30.74M,-30.97M,-1.36,,104.08M,3.58,10.01M,10.89,14.37,3.16,-26.2M,-14.91M,Value,92037,Healthcare,31,"Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.",La Jolla,858 412 5302,CA,1609372800,United States,http://equilliumbio.com,86400,2223 Avenida De La Playa,Biotechnology,Suite 105
t-3,EQ,30972000.0,29040300,3893000,,-6461000,,-6461000,2717000,0,-6610000,-6610000,,-274000,,,,0,0,6610000,0,149000,,-6461000,-6461000,86284000.0,13287000.0,30972000.0,44259000.0,1000.0,-55410000.0,90000.0,97000.0,24083000.0,3387000.0,,97000.0,81000.0,44178000.0,18523000.0,9810000.0,1761000.0,,8455000.0,-61000.0,8455000.0,96000.0,307000.0,96000.0,3469000.0,-2000.0,-5080000.0,7000.0,1063000.0,-157000.0,40791000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,1.3008118,6.1 - 6.285,6.15,6.18,6.31,8,8,finmb_575585027,NasdaqGM,"Equillium, Inc.",USD,137012,296166,-14400000,False,False,us_market,NGM,-1.358,-1.54,-1.32,-4.719697,3.164,5.7708335,0.45916653,0.07956676,6.4944925,-0.2644925,-0.040725663,180921072,-4.0454545,1.9690266,15,America/New_York,EDT,6.23,1630509750,0.07999992,6.13,6.285,6.1,19232,"Equillium, Inc.",2,REGULAR,0,2.76,0.79538906,3.47 - 11.33,-5.1,-0.4501324,3.47,11.33,1620921721,1636369140,1636718400,1.62,,,11.33,3.47,5.77,6.49,137.01k,296.17k,29.04M,,17.96M,52.99%,30.00%,1.14M,9.13,7.18%,3.91%,778.35k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-24.55%,-48.30%,,,,,-30.74M,-30.97M,-1.36,,104.08M,3.58,10.01M,10.89,14.37,3.16,-26.2M,-14.91M,Value,92037,Healthcare,31,"Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.",La Jolla,858 412 5302,CA,1609372800,United States,http://equilliumbio.com,86400,2223 Avenida De La Playa,Biotechnology,Suite 105
